NEW YORK--(BUSINESS WIRE)--Lev Pharmaceuticals, Inc. (“Lev” or the “Company”) (OTCBB:LEVP.OB) announced today that Joshua Schein, Ph.D., Chief Executive Officer of Lev will present at the BIO CEO & Investor Conference 2008, being held February 11-13 at the Waldorf Astoria in New York City. Dr. Schein will present a corporate progress report, including an update on the Company’s lead product candidate, Cinryze™ (C1 inhibitor). The Lev presentation is scheduled to begin at 10:15 AM ET on Tuesday, February 12th.
